Key result
Macitentan fails to improve exercise capacity over placebo in Fontan-palliated patients.
Why the study?
The clinical utility and long-term effects of endothelin receptor antagonists in Fontan-palliated patients remain unclear, and there are currently no approved therapies.
Does macitentan improve peak VO2 in Fontan-palliated patients?
RCT (n=137)
Double-blind
1:1
Yes
Does macitentan improve peak VO2 in Fontan-palliated patients?
In Fontan-palliated patients, macitentan did not significantly improve exercise capacity (peak VO2) or daily physical activity compared to placebo.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The primary end point of RUBATO-DB was not met; macitentan did not improve exercise capacity versus placebo in patients with Fontan palliation. Macitentan was generally well tolerated over long-term treatment.”
“Macitentan, another endothelin receptor antagonist, improved symptoms and exercise capacity in a case report of a failing Fontan patient. However, the RUBATO, the multicenter, double-blind, randomized, placebo-controlled, phase 3 trial on efficacy and safety of macitentan in Fontan palliated patients, showed no significant change in peak VO2 between baseline and week 16 in Fontan patients with NYHA class II-III.”
Macitentan does not improve peak VO2 in Fontan patients; leaves open whether endothelin antagonism confers clinical benefit in this population.
Background The clinical utility and long-term effects of endothelin receptor antagonists (ERAs) in Fontan-palliated patients remain unclear and there are currently no approved therapies. A decline in peak VO2 between consecutive cardiopulmonary exercise tests (CPETs) is highly prognostic for death or transplant in adult Fontan patients, hence its use as a primary endpoint in clinical trials of ERAs in patients with Fontan circulation. Purpose The RUBATO trial aimed to assess the efficacy and safety of macitentan, an endothelin receptor antagonist, in Fontan-palliated patients over 52 weeks. Methods In the multicentre, double-blind, randomised, placebo-controlled, phase 3 RUBATO trial, Fontan-palliated patients were randomised 1:1 to macitentan 10 mg once-daily or placebo for 52 weeks. Eligible patients were aged ≥12 years, in New York Heart Association functional class II or III, had no limitations for CPET (including no pacemakers), had undergone lateral tunnel or extracardiac conduit Fontan (total cavopulmonary connection) >1 year before screening and showed no signs of Fontan failure or clinical deterioration within 3 months before screening. Primary efficacy endpoint was change in peak VO2 from baseline to week 16. Secondary endpoints were change in peak VO2 from baseline over 52 weeks and change in mean count per minute of daily physical activity from baseline to week 16 as measured by an accelerometer. Adverse events were also assessed. Results 137 patients were randomised to macitentan (n=68) or placebo (n=69). 92.7% of patients completed 52 weeks of double-blind treatment: 7 and 3 patients prematurely discontinued study treatment in macitentan and placebo arms, respectively. Patient baseline characteristics are shown in Table 1. At week 16, the mean (SD) change from baseline in peak VO2 was –0.16 (2.86) with macitentan vs –0.67 (2.66) mL/kg/min with placebo (median unbiased estimate of the difference between macitentan and placebo: 0.62 mL/kg/min [99% repeated confidence interval –0.62; 1.85], p=0.1930). No treatment effect was observed in the two secondary endpoints (Table 2): mean (SD) count per minute of daily physical activity decreased from baseline to week 16 by 3.02 (92.44) with macitentan and by 14.34 (117.56) with placebo (p=0.4512). The most common AEs were headache (10.3% vs 8.7% on placebo), nasopharyngitis (5.9% vs 4.3%), and pyrexia (5.9% vs 4.3%). AEs leading to treatment discontinuation were reported in 3 (4.4%) and 1 (1.4%) of macitentan and placebo patients. Conclusion The 52-week RUBATO trial provides an important addition to data on the clinical utility of ERAs in Fontan-palliated patients. The primary efficacy endpoint was not met and no treatment effect was observed for the two secondary endpoints. Macitentan was well tolerated; safety findings were consistent with the known safety profile of macitentan 10 mg. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Actelion Pharmaceuticals Ltd., a Janssen pharmaceutical company of Johnson & Johnson.
No takes yet. Share an insight, caveat, or question.
Clift et al. (2022) conducted an RCT in Fontan-palliated patients (n=137). Macitentan vs. Placebo was evaluated on change in peak VO2 from baseline to week 16 (MD 0.62, 95% CI -0.62 to 1.85, p=0.1930). Macitentan did not improve exercise capacity at week 16 compared to placebo in Fontan-palliated patients.
Synapse has enriched 10 related papers. Consider them for comparative context: